biomarkers

Global DNA microarray market projected to grow from $2.5B in 2025 to $4.7B by 2034 at 7% CAGR, driven by genomic research and personalized medicine demand.

Aclarion appoints Daniel Keefe as Western U.S. Commercial Director to accelerate adoption of its Nociscan diagnostic platform amid triple-digit growth.

Agora integrates thymia's voice biomarker technology into its platform to detect stress and fatigue signals across healthcare, automotive, and workplace sectors.

Theriva Biologics will present expanded VIRAGE trial data for VCN-01 at AACR 2026, with FDA and EMA agreement on Phase 3 design for metastatic pancreatic cancer treatment.

Tempus AI shares jumped 7.3% to $49.34 after 31 cancer research abstracts were accepted for AACR conference, though analyst coverage turns cautious.

Epitopea appoints Dr. Lisa Butterfield, immuno-oncology expert, to Scientific Advisory Board to advance RNA-based cancer immunotherapies.

Aclarion outlines 2026 priorities: pursuing regional insurance reimbursement, releasing CLARITY trial results in Q4 2026, and expanding Nociscan adoption. Strong balance sheet extends to 2028.

Aclarion CEO to present NOCISCAN platform at LSI USA 2026 investor conference, advancing AI-powered diagnostic technology for chronic low back pain identification.

Tempus AI expands multi-year partnership with Merck to develop AI-driven precision medicine biomarkers, though stock declined 1.56% amid broader market weakness.

Clene outlines 2026 regulatory milestones for ALS drug CNM-Au8, including FDA meeting, NDA submission, and Phase 3 trial, backed by $28 million funding.

Abivax presented evidence that obefazimod shows anti-fibrotic potential in IBD treatment with good safety profile. Phase 3 results expected mid-2026.

ALS therapeutics market to more than double by 2035, reaching $1.96 billion. Growth driven by genetic therapies, improved diagnostics, and disease awareness.